Events & Presentations | United Therapeutics Corporation

Forward-Looking Statements

The websites of United Therapeutics Corporation and its subsidiaries (collectively, the Company) include “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements include discussions of our pipeline of products, including anticipated research and development efforts and regulatory approvals, and our expectations concerning future operating results, and any statements that include the words “believe,” “seek,” “expect,” “anticipate,” “forecast,” “project,” “intend,” “estimate,” “should,” “could,” “may,” “will,” “plan,” or similar expressions.

These forward-looking statements are subject to certain risks and uncertainties, such as those described in the Company’s periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in the Company’s periodic reports and documents filed with the Securities and Exchange Commission (SEC), including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, available at the SEC’s website. The Company claims the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

The information contained in this website was current as of the date presented. The Company assumes no duty to update the information to reflect subsequent developments, whether as a result of new information, future events or any other reason. Consequently, investors should not rely upon the information as current or accurate after the date it was added or presented.

This website includes discussions of our product pipeline, including anticipated research and development efforts and projected regulatory approvals. The statements contained on this website may include presentation of clinical data that may be outside the scope of the FDA-approved/cleared product labeling and does not constitute medical advice. To view our FDA approved/cleared product information, please see the following:

https://www.tyvasohcp.com/

https://www.orenitramhcp.com/

https://www.remodulinpro.com/

https://unituxin.com/hcp/

https://www.lungbioengineering.com/hcp/

Decline Accept

Events

Upcoming Events

Past Events